Join to view full profile
2711 Randolph RdSte 400Charlotte, NC 28207
Phone+1 707-342-9577
Fax+1 704-377-0353
Dr. Favaro is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2000 - 2003
Medical University of South CarolinaClass of 2000
Certifications & Licensure
NC State Medical License 2003 - 2027
SC State Medical License 2022 - 2027
TX State Medical License 2002 - 2004
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014, 2017
- CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2012, 2014, 2017
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
- S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- 19 citationsLanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.P Ryan, Ali McBride, David Ray, S Pulgar, Robert A. Ramirez
Journal of Oncology Pharmacy Practice. 2019-03-29 - 31 citationsA Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric AdenocarcinomasHope E. Uronis, Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S. David Hsu
The Oncologist. 2013-03-01 - 66 citationsPhase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate DosingChristina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith O. Hopkins
Clinical Cancer Research. 2011-09-15
Press Mentions
Three Years After COVID-19 Pandemic Began in N.C., Doctor Says Increased Hygiene, Telehealth Here to StayMarch 8th, 2023- Featured Practice: Oncology Specialists of CharlotteJune 18th, 2021
- Cancer Centers Are Suffering Major Shortage of Popular Chemo DrugsJune 21st, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: